Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees

Healthy Q3 For 'Big Three'

The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.

Merck KGaA Darmstadt
• Source: merck kgaa

Although Merck KGaA's life sciences division is driving growth, thanks to additional business related to the COVID-19 pandemic, the German group's healthcare unit enjoyed a strong third quarter, with sales of the checkpoint inhibitor Bavencio and multiple sclerosis drug Mavenclad comfortably exceeding consensus forecasts.

Group net sales jumped by 11.8% to €5.0bn, driven by what Merck calls the 'big three', namely process solutions, semiconductors...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.